Myalepta (metreleptin): inconsistencies in the package leaflet

Table of contents

About

This direct healthcare professional communication (DHPC) contains important information for healthcare professionals prescribing, dispensing or administering the medicine(s). It also includes a communication plan with details of intended recipients and the dissemination date.

Documents

Key facts

Medicine name
Myalepta
Active substance
Metreleptin
Therapeutic area (MeSH)
Lipodystrophy, Familial Partial
Procedure number
EMEA/H/C/004218
DHPC type
Quality defect
Human ATC code
A16AA
Dissemination date
18/06/2020

How useful was this page?

Add your rating